Divergent Pathways to Cutaneous Melanoma

  • David C. Whiteman
  • Adèle C. Green
Chapter

Abstract

Cutaneous melanomas arise on all skin surfaces, but they do so at markedly different rates. Understanding the reasons behind site-specific differences in melanoma rates should help unravel some of the inconsistent findings reported from epidemiological studies and provide the basis for informed preventive activities. Although exposure to sunlight is generally accepted to determine the rate at which melanocytes at any particular anatomical site are transformed, there are also likely to be anatomical differences (within a host) and constitutional differences (among hosts) in the susceptibility of melanocytes to progress to neoplasia. The contributions of these competing causal factors (environmental, anatomical, and genetic) to the development of melanoma have not been collectively studied, yet this is necessary if deeper understanding of melanoma pathogenesis is to yield tangible public health benefits. Here, we review the literature for evidence of causal heterogeneity for melanoma and present the findings of a recent epidemiological study from Queensland, Australia.

Key Words

Melanoma causality sunlight risk factor occupation nevus solar keratosis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kricker A, Vajdic C, Armstrong B. Ocular melanoma and cutaneous melanoma. Int J Cancer 2003;104:259.PubMedCrossRefGoogle Scholar
  2. 2.
    Cree IA. Cell cycle and melanoma-two different tumours from the same cell type [editorial; comment]. J Pathol 2000;191:112–124.PubMedCrossRefGoogle Scholar
  3. 3.
    Ridgeway CA, Hieken TJ, Ronan SG, Kim DK, Das Gupta TK. Acral lentiginous melanoma. Arch Surg 1995;130:88–92.PubMedGoogle Scholar
  4. 4.
    Green A, McCredie M, MacKie R, et al. A case-control study of melanomas of the soles and palms (Australia and Scotland). Cancer Causes Control 1999;10:21–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995;33:923–936.PubMedCrossRefGoogle Scholar
  6. 6.
    Cox NH, Aitchison TC, Sirel JM, MacKie RM. Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br J Cancer 1996;73:940–944.PubMedGoogle Scholar
  7. 7.
    Deveraj VS, Moss ALH, Briggs JC. Desmoplastic melanoma: A clinico-pathological review. Br J Plastic Surgery 1992;45:595–598.CrossRefGoogle Scholar
  8. 8.
    Ackerman AB. Malignant melanoma: a unifying concept. Hum Pathol 1980;11:591–595.PubMedCrossRefGoogle Scholar
  9. 9.
    Green A. A theory of site distribution of melanomas: Queensland, Australia. Cancer Causes Control 1992;3:513–516.PubMedCrossRefGoogle Scholar
  10. 10.
    Green A, MacLennan R, Siskind V. Common acquired naevi and the risk of malignant melanoma. Int J Cancer 1985;35:297–300.PubMedCrossRefGoogle Scholar
  11. 11.
    Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459–468.PubMedCrossRefGoogle Scholar
  12. 12.
    Holman CD, Armstrong BK. Pigmentary traits, ethnic origin, benign nevi, and family history as risk factors for cutaneous malignant melanoma. J Natl Cancer Inst 1984;72:257–266.PubMedGoogle Scholar
  13. 13.
    Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer 1995;62:377–381.PubMedCrossRefGoogle Scholar
  14. 14.
    Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. Int J Cancer 1995;62:367–376.PubMedCrossRefGoogle Scholar
  15. 15.
    Osterlind A, Hou-Jensen K, Moller-Jensen O. Incidence of cutaneous malignant melanoma in Denmark 1978–1982. Anatomic site distribution, histologic types and comparison with non-melanoma skin cancer. Br J Cancer 1988;58:385–391.PubMedGoogle Scholar
  16. 16.
    Magnus K. Habits of sun exposure and risk of malignant melanoma: an analysis of incidence rates in Norway 1955–1977 by cohort,sex, age and primary tumor site. Cancer 1981;48:2329–2335.PubMedCrossRefGoogle Scholar
  17. 17.
    Popescu NA, Beard CM, Treacy PJ, Winkelmann RK, O’Brien PC, Kurland LT. Cutaneous malignant melanoma in Rochester, Minnesota: trends in incidence and survivorship, 1950 through 1985. Mayo Clin Proc 1990;65:1293–1302.PubMedGoogle Scholar
  18. 18.
    Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in South Sweden 1965, 1975, and 1985. A histopathologic review. Cancer 1994;73:1625–1630.PubMedCrossRefGoogle Scholar
  19. 19.
    Green A, MacLennan R, Youl P, Martin N. Site distribution of cutaneous melanoma in Queensland. Int J Cancer 1993;53:232–236.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen YT, Zheng T, Holford TR, Berwick M, Dubrow R. Malignant melanoma incidence in Connecticut (United States): time trends and age-period-cohort modeling by anatomic site. Cancer Causes Control 1994;5:341–350.PubMedCrossRefGoogle Scholar
  21. 21.
    Houghton A, Flannery J, Viola MV. Malignant melanoma in Connecticut and Denmark. Int J Cancer 1980;25:95–104.PubMedCrossRefGoogle Scholar
  22. 22.
    Bulliard J-L. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000;85:627–632.PubMedCrossRefGoogle Scholar
  23. 23.
    Teppo L, Pakkanen M, Hakulinsen T. Sunlight as a risk factor of malignant melanoma of the skin. Cancer 1978;41:2018–27.PubMedCrossRefGoogle Scholar
  24. 24.
    Fincham SM, Hanson J, Berkel J. Patterns and risks of cancer in farmers in Alberta. Cancer 1992;69:1276–1285.PubMedCrossRefGoogle Scholar
  25. 25.
    Lee JAH, Strickland D. Malignant melanoma: social status and outdoor work. Br J Cancer 1980;41:757–763.PubMedGoogle Scholar
  26. 26.
    Vagero D, Swerdlow AJ, Beral V. Occupation and malignant melanoma: a study based on cancer registration data in England and Wales and in Sweden. British Journal of Industrial Medicine 1990;47:317–324.PubMedGoogle Scholar
  27. 27.
    Beral V, Robinson N. The relationship of malignant melanoma, basal and squamous skin cancers to indoor and outdoor work. Br J Cancer 1981;44:886–891.PubMedGoogle Scholar
  28. 28.
    Vagero D, Ringback G, Kiviranta H. Melanoma and other tumours of the skin among office, other indoor workers and outdoor workers in Sweden 1961–1979. Br J Cancer 1986;53:507–512.PubMedGoogle Scholar
  29. 29.
    Linet MS, Malker HS, Chow WH, et al. Occupational risks for cutaneous melanoma among men in Sweden. J Occup Environ Med 1995;37:1127–35 PA Hospital Journal holding: 37(995)–42(2000);43(1)-Departmental Holdings holding: 37(1995)–42(2000);43(1)-.PubMedCrossRefGoogle Scholar
  30. 30.
    Hakanson N, Floderus B, Gustavsson P, Feychting M, Hallin N. Occupational sunlight exposure and cancer incidence among Swedish construction workers. Epidemiology 2001;12:552–557.CrossRefGoogle Scholar
  31. 31.
    Diffey BL, Gies HP. The confounding influence of sun exposure in melanoma. Lancet 1998;351:1101–1102.PubMedCrossRefGoogle Scholar
  32. 32.
    Elwood JM, Diffey BL. A consideration of ambient solar ultraviolet radiation in the interpretation of studies of the aetiology of melanoma. Melanoma Res 1993;3:113–122.PubMedGoogle Scholar
  33. 33.
    Thieden E, Agren MS, Wulf HC. Solar UVR exposures of indoor workers in a Working and a Holiday Period assessed by personal dosimeters and sun exposure diaries. Photodermatol Photoimmunol Photomed 2001;17:249–255.PubMedCrossRefGoogle Scholar
  34. 34.
    Vagero D, Persson G. Risks, survival and trends of malignant melanoma among white and blue collar workers in Sweden. Soc Sci Med 1984;19:475–478.PubMedCrossRefGoogle Scholar
  35. 35.
    Rimpela AH, Pukkala EI. Cancers of affluence: positive social class gradient and rising incidence trend in some cancer forms. Soc Sci Med 1987;24:601–606.PubMedCrossRefGoogle Scholar
  36. 36.
    Faggiano F, Partanen T, Kogevinas M, Boffetta P. Socioeconomic differences in cancer incidence and mortality. IARC Sci Publ 1997:65–176.Google Scholar
  37. 37.
    Pearce N, Bethwaite P. Social class and male cancer mortality in New Zealand, 1984–7. NZ Med J 1997;110:200–202.Google Scholar
  38. 38.
    Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198–203.PubMedCrossRefGoogle Scholar
  39. 39.
    Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001;12:69–82.PubMedCrossRefGoogle Scholar
  40. 40.
    Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984;73:75–82.PubMedGoogle Scholar
  41. 41.
    Weinstock MA, Colditz GA, Willett WC, Stampfer MJ, Bronstein BR, Mihm MC, et al. Moles and site-specific cutaneous malignant melanoma in women. J Natl Cancer Inst 1989;81:948–952.PubMedCrossRefGoogle Scholar
  42. 42.
    Chen YT, Dubrow R, Holford TR, et al. Malignant melanoma risk factors by anatomic site: a casecontrol study and polychotomous logistic regression analysis. Int J Cancer 1996;67:636–643.PubMedCrossRefGoogle Scholar
  43. 43.
    Kruger S, Garbe C, Buttner P, Stadler R, Guggenmoos-Holzmann I, Orfanos CE. Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. J Am Acad Dermatol 1992;26:920–926.PubMedCrossRefGoogle Scholar
  44. 44.
    Rieger E, Soyer HP, Garbe C, et al. Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German central malignant-melanoma registry. Int J Cancer 1995;62:393–397.PubMedCrossRefGoogle Scholar
  45. 45.
    Bataille V, Sasieni P, Grulich A, et al. Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi. Int J Cancer 1998;78:8–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Urso C, Giannotti V, Reali UM, Giannotti B, Bondi R. Spatial association of melanocytic naevus and melanoma. Melanoma Res 1991;1:245–249.PubMedCrossRefGoogle Scholar
  47. 47.
    Marks R, Dorevitch AP, Mason G. Do all melanomas come from “moles”? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990;31:77–80PubMedCrossRefGoogle Scholar
  48. 48.
    Kaddu S, Smolle J, Zenahlik P, Hofmann-Wellenhof R, Kerl H. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res 2002;12:271–278.PubMedCrossRefGoogle Scholar
  49. 49.
    Carli P, Massi D, Santucci M, Biggeri A, Gianotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case-control study. J Am Acad Dermatol 1999;40:549–557.PubMedCrossRefGoogle Scholar
  50. 50.
    Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995;33:1000–1007.PubMedCrossRefGoogle Scholar
  51. 51.
    Grulich AE, Bataille V, Swerdlow AJ, al. e. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 1996;67:485–491.PubMedCrossRefGoogle Scholar
  52. 52.
    Merlino G, Noonan FP. Modeling gene-environment interactions in malignant melanoma. Trends Mol Med 2003;9:102–108.PubMedCrossRefGoogle Scholar
  53. 53.
    Silvers WK, Mintz B. Differences in latency and inducibility of mouse skin melanomas depending on the age and anatomic site of the skin. Cancer Res 1998;58:630–602.PubMedGoogle Scholar
  54. 54.
    Green A, Neale R, Kelly R, et al. An animal model for human melanoma. Photochem Photobiol 1996;64:577–580.PubMedGoogle Scholar
  55. 55.
    Ziegler A, Jonason A, Simon J, Leffell D, Brash DE. Tumor suppressor gene mutations and photocarcinogenesis. Photochem Photobiol 1996;63:432–435.PubMedGoogle Scholar
  56. 56.
    Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 1991;51:5976–5979.PubMedGoogle Scholar
  57. 57.
    Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the cevelopment of malignant melanoma. Cancer Res 1993;53:2235–2238.PubMedGoogle Scholar
  58. 58.
    Cristofolini M, Boi S, Girlando S, et al. p53 Protein Expression in Nevi and Melanomas. Arch Dermatol 1993;129:739–743.PubMedCrossRefGoogle Scholar
  59. 59.
    Platz A, Ringborg U, Grafstrom E, Hoog A, Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res 1995;5:101–106.PubMedCrossRefGoogle Scholar
  60. 60.
    Sparrow LE, Soong R, Dawkins HJS, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995;5:93–100.PubMedCrossRefGoogle Scholar
  61. 61.
    Albino AP, Vidal MJ, McNutt NS, et al. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994;4:35–45.PubMedCrossRefGoogle Scholar
  62. 62.
    Castresana JS, Rubio MP, Vazquez JJ, et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993 1993;554:562–565.CrossRefGoogle Scholar
  63. 63.
    Florenes VA, Oyjord T, Holm R, Borresen A-L, Nesland JM, Fodstad O. TP53 allele loss, mutations and expressions in malignant melanoma. Br J Cancer 1994;69:253–259.PubMedGoogle Scholar
  64. 64.
    Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998;77:843–848.PubMedCrossRefGoogle Scholar
  65. 65.
    Kim YC, Lee MG, Cho SH, Lee JH, Lee DH, Ahn BK. The relation between p53 expression and physical site of melanoma: an immunohistochemical study. Br J Dermatol 2003;149:1299–1300.PubMedCrossRefGoogle Scholar
  66. 66.
    Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997;74:535–539.PubMedCrossRefGoogle Scholar
  67. 67.
    Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK. Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 2002;12:453–463.PubMedCrossRefGoogle Scholar
  68. 68.
    Essner R, Kuo CT, Wang H, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 1998;82:309–316.PubMedCrossRefGoogle Scholar
  69. 69.
    Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97–99.PubMedCrossRefGoogle Scholar
  70. 70.
    Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 1996;15:77–88.PubMedCrossRefGoogle Scholar
  71. 71.
    Pavey SJ, Cummings MC, Whiteman DC, et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002;12:539–547.PubMedCrossRefGoogle Scholar
  72. 72.
    Wang YL, Uhara H, Yamazaki Y, Nikaido T, Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br J Dermatol 1996;134:269–275.PubMedCrossRefGoogle Scholar
  73. 73.
    Keller-Melchior R, Schmidt R, Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 1998;110:932–928.PubMedCrossRefGoogle Scholar
  74. 74.
    Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg 1999;3:293–297.PubMedGoogle Scholar
  75. 75.
    Morita R, Fujimoto A, Hatta N, Takehara K, Takata M. Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol 1998;111:919–924.PubMedCrossRefGoogle Scholar
  76. 76.
    Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999;18(52):7462–7468.PubMedCrossRefGoogle Scholar
  77. 77.
    Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267–273.PubMedCrossRefGoogle Scholar
  78. 78.
    Boni R, Vortmeyer AO, Burg G, Hofbauer G, Zhuang Z. The PTEN tumour suppressor gene and malignant melanoma. Melanoma Research 1998;8(4):300–302.PubMedCrossRefGoogle Scholar
  79. 79.
    Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221–5.PubMedGoogle Scholar
  80. 80.
    Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16:3397–3402.PubMedCrossRefGoogle Scholar
  81. 81.
    Pollock PM, Walker GJ, Glendening JM, et al. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 2002;12:565–575.PubMedCrossRefGoogle Scholar
  82. 82.
    Whiteman DC, Zhou X-P, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clincopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 2002;99:63–67.PubMedCrossRefGoogle Scholar
  83. 83.
    Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527–532.PubMedCrossRefGoogle Scholar
  84. 84.
    Pollock PM, Meltzer PS. Lucky draw in the gene raffle. Nature 2002;417:906–907.PubMedCrossRefGoogle Scholar
  85. 85.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.PubMedCrossRefGoogle Scholar
  86. 86.
    van-’t-Veer LJ, Burgering BM, Versteeg R, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989;9:3114–3116.PubMedGoogle Scholar
  87. 87.
    van-Elsas A, Zerp SF, van-der-Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883–893.PubMedGoogle Scholar
  88. 88.
    Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 1998;111:757–761.PubMedCrossRefGoogle Scholar
  89. 89.
    Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004;109:377–384.PubMedCrossRefGoogle Scholar
  90. 90.
    Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883–3885.PubMedGoogle Scholar
  91. 91.
    Yazdi AS, Palmedo G, Flaig MJ, et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003;121:1160–1162.PubMedCrossRefGoogle Scholar
  92. 92.
    Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483–6488.PubMedGoogle Scholar
  93. 93.
    Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955–3957.PubMedGoogle Scholar
  94. 94.
    Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003;22:9217–9224.PubMedCrossRefGoogle Scholar
  95. 95.
    Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003;95:1878–1890.PubMedGoogle Scholar
  96. 96.
    Uribe P, Wistuba, II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365–370.PubMedCrossRefGoogle Scholar
  97. 97.
    Papp T, Pemsel H, Zimmermann R, Bastrop R, Weiss DG, Schiffmann D. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999;36:610–614.PubMedGoogle Scholar
  98. 98.
    Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806–812.PubMedCrossRefGoogle Scholar
  99. 99.
    Carli P, Palli D. Re: Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:1801; author reply, 2.PubMedGoogle Scholar
  100. 100.
    Lancaster HO. Some geographical aspects of the mortality from melanoma in Europeans. Med J Aust 1956;1:1082–1087.Google Scholar
  101. 101.
    Armstrong BK. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun. J Dermatol Surg Oncol 1988;14:835–849.PubMedGoogle Scholar
  102. 102.
    Libow LF, Scheide S, DeLeo VA. Ultraviolet radiation acts as an independent mitogen for normal human melanocytes in culture. Pigment Cell Res 1988;1:397–401.PubMedCrossRefGoogle Scholar
  103. 103.
    Stierner U, Rosdahl I, Augustsson A, Kagedal B. UVB irradiation induces melanocyte increase in both exposed and shielded human skin. J Invest Dermatol 1989;92:561–564.PubMedCrossRefGoogle Scholar
  104. 104.
    Autier P, Boniol M, Severi G, et al. The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res 2001;11:123–131.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, N.J. 2006

Authors and Affiliations

  • David C. Whiteman
    • 1
  • Adèle C. Green
    • 1
  1. 1.Division of Population Studies and Human GeneticsQueensland Institute of Medical ResearchBrisbaneAustralia

Personalised recommendations